| 1.75 -0.12 (-6.42%) | 08-17 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.68  |
1-year : | 3.11 |
| Resists | First : | 2.3 |
Second : | 2.66 |
| Pivot price | 1.93 |
|||
| Supports | First : | 1.71 |
Second : | 1.42 |
| MAs | MA(5) : | 1.85 |
MA(20) : | 1.97 |
| MA(100) : | 3.94 |
MA(250) : | 7.67 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 20.5 |
| RSI | RSI(14): 29.7 |
|||
| 52-week | High : | 14.64 | Low : | 1.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CVKD ] has closed below the lower bollinger band by 0.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CVKD ] is to continue within current trading range. It is unclear right now based on current values. 81.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.92 | 1.92 - 1.93 |
| Low: | 1.78 - 1.79 | 1.79 - 1.8 |
| Close: | 1.86 - 1.87 | 1.87 - 1.88 |
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Thu, 13 Aug 2026
Cadrenal CAD-1005 data show more than 25% absolute drop in clot events - Stock Titan
Fri, 07 Aug 2026
Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock Titan
Wed, 05 Aug 2026
CVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Wed, 01 Jul 2026
Cadrenal Therapeutics Announces $3 Million Private Placement with Potential Additional $5.8 Million from Warrants - Quiver Quantitative
Tue, 30 Jun 2026
Cadrenal raises $3M now, with $5.8M more possible from warrants - Stock Titan
Thu, 25 Jun 2026
CVKD Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 56 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -5.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -139.3 % |
| Return on Equity (ttm) | -300.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | 2.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|